Pfizer-Allergan and the New U.S. Tax Inversion Rule

The video discusses the Pfizer-Analogon deal, focusing on tax inversion benefits and financial calculations. It highlights the need for significant cash inflow for the deal to be accretive, primarily through buybacks. The discussion also covers regulatory uncertainties and potential risks, including the impact of new Treasury rules on previous deals. The complexity of the situation is emphasized, with no clear answers on how regulations will affect the deal's future.

How might previous deals be affected by the new regulations?

What uncertainties exist regarding the enforcement of the new rules?